Uncover key drivers, emerging technologies, and competitive movements shaping the endocrine peptide test market from 2026–2035 with trusted insights from The Business Research Company
What is the expected shift in the Endocrine Peptide Test Market’s size between 2026 and 2030?
The endocrine peptide test market size has shown strong growth in recent years. It is projected to expand from $9.95 billion in 2025 to $10.88 billion in 2026, at a compound annual growth rate (CAGR) of 9.3%. This historical growth can be attributed to factors such as an increase in endocrine disorders, the expansion of diagnostic laboratories, greater awareness of hormone imbalances, advancements in immunoassay techniques, and the broadening scope of clinical endocrinology.
The endocrine peptide test market size is projected for substantial expansion in the coming years. This market is predicted to reach $14.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. Key factors driving this growth during the forecast period include precision medicine adoption, advanced biomarker research, automation in diagnostic labs, personalized endocrine care, and a growing demand for early diagnosis. Prominent trends anticipated over the forecast period encompass rising demand for hormone disorder diagnostics, increased use of peptide biomarkers, continued growth in early endocrine disease detection, the expansion of laboratory-based specialized testing, and a strong focus on accurate hormonal monitoring.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp
Which Drivers Are Shaping Strategic Decisions In The Endocrine Peptide Test Market?
The increasing occurrence of diabetes is anticipated to fuel the expansion of the endocrine peptide test market in the future. Diabetes is defined as a collection of conditions characterized by elevated blood sugar (glucose) concentrations. The rise in diabetes cases is attributable to various elements, including poor dietary habits, inactive lifestyles, inherited susceptibility, and an older demographic. Endocrine peptide tests, such as hemoglobin A1c, fasting plasma glucose, and C-peptide examinations, are employed for diabetes management to identify the ailment, track glucose concentrations, and evaluate insulin generation and responsiveness. For example, data released in June 2024 by the UK’s National Health Service (NHS), a government body, indicated a substantial increase in diabetes diagnoses among individuals under 40, growing from 173,166 in 2022 to 216,440 in 2023. This marked expansion highlights an alarming pattern of escalating diabetes prevalence within younger age groups. Consequently, the increasing incidence of diabetes is a primary motivator for the endocrine peptide test market.
What Segment Classifications Make Up The Endocrine Peptide Test Market?
The endocrine peptide test market covered in this report is segmented –
1) By Test-Type: Dehydroepiandrosterone Sulphate, Progesterone, Luteinizing Hormone, Thyroid Prolactin, Oestradiol, Human Chorionic Gonadotropin, Thyroid-Stimulating Hormone, Other Test-Types
2) By Technology: Mass Spectroscopy, Immunoassay, Chromatography, Nucleic Acid Based, Other Technologies
3) By End-User: Clinics, Healthcare Centers, Hospitals, Commercial Laboratories
Subsegments:
1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)
2) By Progesterone: Immunoassay Tests, Chemiluminescence Assays, ELISA Tests
3) By Luteinizing Hormone: Immunoassay Tests, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA)
4) By Thyroid Prolactin: Immunoassay Tests, Chemiluminescence Assays, Radioimmunoassay (RIA)
5) By Oestradiol: Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)
6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests, Chemiluminescence Assays, Enzyme Immunoassay (EIA)
7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests, Radioimmunoassay (RIA), Enzyme-Linked Immunosorbent Assay (ELISA)
8) By Other Test-Types: Cortisol, Insulin, Growth Hormone (GH), Parathyroid Hormone (PTH)
Which Competitive Trends Are Impacting The Structure Of The Endocrine Peptide Test Market?
Key players in the endocrine peptide test market are developing immunoassay testing systems to enhance the accuracy, sensitivity, and speed of endocrine peptide testing. These systems employ antibodies to detect and measure specific peptides in blood or urine samples, providing healthcare professionals with valuable information regarding hormone levels and endocrine function. For example, in July 2023, Siemens Healthineers, a German-based healthcare services company, launched the Atellica CI Analyzer, a compact system for immunoassay and clinical chemistry testing, including endocrine peptide assays. The analyzer also includes a reproductive endocrinology menu with anti-Mullerian hormone (AMH) for determining ovarian reserve and sFlt-1 and PlGF (placental growth factor) to aid in the prognosis of preeclampsia. The Atellica CI Analyzer is engineered to deliver quality results quickly and consistently, with a capacity of up to 1000 tests per hour, offering workflow efficiency and flexibility to help laboratories meet evolving testing demands.
Which Major Industry Participants Are Leading The Endocrine Peptide Test Market Growth?
Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report
Which Region Is Projected To Lead The Endocrine Peptide Test Market During The Forecast Period?
North America was the largest region in the endocrine peptide test market in 2025. The regions covered in the endocrine peptide test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Endocrine Peptide Test Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=16675&type=smp
Browse Through More Reports Similar to the Global Endocrine Peptide Test Market 2026, By The Business Research Company
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Endocrine Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report
Thyroid Function Test Market Report 2026
https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model